Repository logo

Regulatory B cell-specific interleukin-10 is dispensable for atherosclerosis development in mice.

Accepted version



Change log


Sage, Andrew P 
Nus, Meritxell 
Baker, Lauren L 
Finigan, Alison J 
Masters, Leanne M 


OBJECTIVE: To determine the role of regulatory B cell-derived interleukin (IL)-10 in atherosclerosis. APPROACH AND RESULTS: We created chimeric Ldlr(-/-) mice with a B cell-specific deficiency in IL-10, and confirmed that purified B cells stimulated with lipopolysaccharide failed to produce IL-10 compared with control Ldlr(-/-) chimeras. Mice lacking B-cell IL-10 demonstrated enhanced splenic B-cell numbers but no major differences in B-cell subsets, T cell or monocyte distribution, and unchanged body weights or serum cholesterol levels compared with control mice. After 8 weeks on high-fat diet, there were no differences in aortic root or aortic arch atherosclerosis. In addition to plaque size, plaque composition (macrophages, T cells, smooth muscle cells, and collagen) was similar between groups. CONCLUSIONS: In contrast to its prominent regulatory role in many immune-mediated diseases and its proposed modulatory role in atherosclerosis, B cell-derived IL-10 does not alter atherosclerosis in mice.



atherosclerosis, interleukins, lymphocytes, Animals, Aorta, Aortic Diseases, Atherosclerosis, B-Lymphocytes, Regulatory, Biomarkers, Cells, Cultured, Diet, High-Fat, Disease Models, Animal, Interleukin-10, Male, Mice, Inbred C57BL, Mice, Knockout, Plaque, Atherosclerotic, Receptors, LDL, Time Factors

Journal Title

Arterioscler Thromb Vasc Biol

Conference Name

Journal ISSN


Volume Title



Ovid Technologies (Wolters Kluwer Health)
British Heart Foundation (None)
This work was funded by the British Heart Foundation (to Z.M.). M. N. has received funding from the People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (FP7/2007-2013) under REA grant agreement n° 608765.